ESMO 2021

Ladiratuzumab Vedotin | Solid Tumors | Abstract #972

Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (SGNLVA-005, Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #3557

Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line (1L) Therapies for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)

Tucatinib | Breast Cancer | Abstract #1770

HER2CLIMB-04: Phase 2 Trial of Tucatinib + Trastuzumab Deruxtecan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer With and Without Brain Metastases (Trial in Progress)

Tucatinib | Gastrointestinal Carcinoma | Abstract #1092

MOUNTAINEER-02: Phase 2/3 Study of Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC): (Trial in Progress)

SGN-B6A | Solid Tumors | Abstract #2946

A First-In-Human Trial of the Integrin Beta-6-Targeted Antibody-Drug Conjugate, SGN-B6A, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)

Brentuximab Vedotin | NSCLC or Cutaneous Melanoma | Abstract #3027

A Phase 2 Trial of Pembrolizumab and Brentuximab Vedotin in Patients With Metastatic Solid Malignancies After Progression on Prior Programmed Cell Death Protein-1 Inhibitors (SGN35-033, Trial in Progress)

SGN-STNV | Solid Tumors | Abstract #3325

A Phase 1 Study of SGN-STNV, A Novel Antibody-Drug Conjugate Targeting Sialyl-Thomsen-Nouveau Antigen (STN), in Adults With Advanced Solid Tumors (SGNSTNV-001, Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #3252

Treatment Patterns Among Patients With Advanced Urothelial Carcinoma (aUC) in the US

Tucatinib | Gastrointestinal Cancers | Abstract #541

Phase 1B/2 Open-Label, Dose Escalation and Expansion Trial of Tucatinib in Combination with Trastuzumab and Oxaliplatin-Based Chemotherapy in Patients With Unresectable or Metastatic HER2+ Gastrointestinal Cancers (Trial in Progress)

Tucatinib | Solid Tumors | Abstract #1003

SGNTUC-019: Phase 2 Basket Study of Tucatinib and Trastuzumab in Previously Treated Solid Tumors With HER2 Alterations (Trial in Progress)

SEA-TGT | Advanced Malignancies | Abstract #3661

Phase 1 Study of Effector Function Enhanced Monoclonal Antibody, SEA-TGT, in Advanced Malignancies (SGNTGT-001, Trial in Progress)

Tucatinib | Colorectal Cancer | Abstract #3027

Characteristics and Treatment Patterns Among Patients With HER2-Amplified Advanced/Metastatic Colorectal Cancer (mCRC): A Clinical-Genomic Database Study

Ladiratuzumab Vedotin | Breast Cancer | Abstract #1378

Weekly Ladiratuzumab Vedotin Monotherapy for Metastatic Triple Negative Breast Cancer

Tisotumab Vedotin | Solid Tumors | Abstract #646

innovaTV 207: New Dosing Cohort in the Open Label Phase 2 Study of Tisotumab Vedotin in Solid Tumors

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #1151

Analysis of Hard-to-Treat Subgroups From EV-301, a Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy for Previously Treated Advanced Urothelial Carcinoma

Tisotumab Vedotin | Cervical Cancer | Abstract #3107

Tisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205